Jinling Pharmaceutical Company Limited (SHE:000919)
China
· Delayed Price · Currency is CNY 7.39
+0.07 (0.96%)
Apr 30, 2026, 3:04 PM CST
SHE:000919 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 3,172 | 3,256 | 3,164 | 2,649 | 2,789 | Upgrade
|
| Other Revenue | 25.77 | 25.02 | 29.52 | 22.15 | 19.62 | Upgrade
|
| Revenue | 3,197 | 3,281 | 3,194 | 2,671 | 2,809 | Upgrade
|
| Revenue Growth (YoY) | -2.56% | 2.74% | 19.58% | -4.91% | 12.18% | Upgrade
|
| Cost of Revenue | 2,531 | 2,676 | 2,557 | 2,142 | 2,181 | Upgrade
|
| Gross Profit | 665.96 | 605.17 | 637.06 | 528.55 | 628.17 | Upgrade
|
| Selling, General & Admin | 507.86 | 446.73 | 460.88 | 383.48 | 384.3 | Upgrade
|
| Research & Development | 110.14 | 110.69 | 79.14 | 74.17 | 57.01 | Upgrade
|
| Other Operating Expenses | 23 | 20.68 | 13 | 18.21 | 19.28 | Upgrade
|
| Operating Expenses | 641 | 579.86 | 556.22 | 477.52 | 458.93 | Upgrade
|
| Operating Income | 24.96 | 25.31 | 80.84 | 51.03 | 169.24 | Upgrade
|
| Interest Expense | -5.21 | -2.2 | -1.3 | -0.26 | -0.29 | Upgrade
|
| Interest & Investment Income | 49.38 | 63.91 | 58.14 | 34.98 | 46.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.01 | 0.04 | 0.02 | 0.08 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 8.4 | 1.73 | -1.07 | -1.45 | -1.42 | Upgrade
|
| EBT Excluding Unusual Items | 77.54 | 88.8 | 136.63 | 84.38 | 213.92 | Upgrade
|
| Impairment of Goodwill | -18.05 | -86.3 | - | - | -45.97 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.11 | 14.39 | -0.96 | -27.14 | -29.95 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.39 | 21.34 | -0.56 | 61.83 | 51.98 | Upgrade
|
| Asset Writedown | -0.91 | -10.01 | -0.15 | - | -1.56 | Upgrade
|
| Other Unusual Items | 7.1 | 11.8 | 13.4 | 8.71 | 6.38 | Upgrade
|
| Pretax Income | 65.19 | 40.01 | 148.36 | 127.77 | 194.81 | Upgrade
|
| Income Tax Expense | 13.9 | 22.05 | 19.6 | 13.9 | 41.88 | Upgrade
|
| Earnings From Continuing Operations | 51.29 | 17.95 | 128.76 | 113.87 | 152.94 | Upgrade
|
| Minority Interest in Earnings | 2.62 | 22.46 | -22.57 | -8.58 | -32.31 | Upgrade
|
| Net Income | 53.91 | 40.41 | 106.19 | 105.28 | 120.63 | Upgrade
|
| Net Income to Common | 53.91 | 40.41 | 106.19 | 105.28 | 120.63 | Upgrade
|
| Net Income Growth | 33.42% | -61.95% | 0.87% | -12.72% | 85.19% | Upgrade
|
| Shares Outstanding (Basic) | 622 | 593 | 504 | 504 | 504 | Upgrade
|
| Shares Outstanding (Diluted) | 622 | 593 | 504 | 504 | 504 | Upgrade
|
| Shares Change (YoY) | 4.95% | 17.56% | 0.01% | -0.02% | -0.01% | Upgrade
|
| EPS (Basic) | 0.09 | 0.07 | 0.21 | 0.21 | 0.24 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.07 | 0.21 | 0.21 | 0.24 | Upgrade
|
| EPS Growth | 27.13% | -67.63% | 0.86% | -12.70% | 85.22% | Upgrade
|
| Free Cash Flow | 16.34 | -47.44 | -25.85 | -49.05 | 129.26 | Upgrade
|
| Free Cash Flow Per Share | 0.03 | -0.08 | -0.05 | -0.10 | 0.26 | Upgrade
|
| Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 | Upgrade
|
| Gross Margin | 20.83% | 18.44% | 19.95% | 19.79% | 22.36% | Upgrade
|
| Operating Margin | 0.78% | 0.77% | 2.53% | 1.91% | 6.02% | Upgrade
|
| Profit Margin | 1.69% | 1.23% | 3.33% | 3.94% | 4.29% | Upgrade
|
| Free Cash Flow Margin | 0.51% | -1.45% | -0.81% | -1.84% | 4.60% | Upgrade
|
| EBITDA | 168.35 | 180.06 | 229.81 | 173.57 | 291.14 | Upgrade
|
| EBITDA Margin | 5.27% | 5.49% | 7.20% | 6.50% | 10.37% | Upgrade
|
| D&A For EBITDA | 143.38 | 154.75 | 148.97 | 122.54 | 121.9 | Upgrade
|
| EBIT | 24.96 | 25.31 | 80.84 | 51.03 | 169.24 | Upgrade
|
| EBIT Margin | 0.78% | 0.77% | 2.53% | 1.91% | 6.02% | Upgrade
|
| Effective Tax Rate | 21.32% | 55.12% | 13.21% | 10.88% | 21.50% | Upgrade
|
| Revenue as Reported | 3,197 | 3,281 | 3,194 | 2,671 | 2,809 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.